Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levisoprenaline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 7/20 | 1.00 |
| ▸ | ADRB1 known ✓ | P08588 | 5/20 | 1.00 |
| ▸ | ADRB3 known ✓ | P13945 | 5/20 | 1.00 |
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | TSHR | P16473 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 4/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 4/20 | 1.00 |
| ▸ | MTOR | P42345 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | DRD2 | P14416 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isoproterenol SCHEMBL29519146 | 1.00 | MAPT (1.00) | MAPTADRB2TDP1KDM4EADRB1 | |
| Levisoprenaline SCHEMBL29620666 | 1.00 | MAPT (1.00) | MAPTADRB2TDP1KDM4EADRB1 | |
| Isoproterenol SCHEMBL4165 | 1.00 | MAPT (1.00) | MAPTADRB2TDP1KDM4EADRB1 | |
| Isoproterenol SCHEMBL29386243 | 1.00 | MAPT (1.00) | MAPTADRB2TDP1KDM4EADRB1 | |
| Isoproterenol SCHEMBL3253794 | 1.00 | MAPT (1.00) | MAPTADRB2TDP1KDM4EADRB1 | |
| Isoproterenol SCHEMBL4166 | 1.00 | MAPT (1.00) | MAPTADRB2TDP1KDM4EADRB1 | |
| Isoproterenol SCHEMBL7627 | 0.98 | MAPT (1.00) | MAPTADRB2TDP1KDM4EADRB1 | |
| Levisoprenaline SCHEMBL4745572 | 0.98 | MAPT (1.00) | MAPTADRB2TDP1KDM4EADRB1 | |
| Isoproterenol SCHEMBL6151626 | 0.98 | MAPT (0.97) | MAPTADRB2TDP1KDM4EADRB1 | |
| Isoproterenol SCHEMBL3672791 | 0.98 | MAPT (1.00) | MAPTADRB2TDP1KDM4EADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11819535-B2 | Composition and methods for regulating extracellular matrix accumulation | UNIVERSITY HEALTH NETWORK (CA) | 2023-11-21 | — | — | US | claimed |
| CN-113260423-A | Topical application composition and method for promoting optimal skin white adipose tissue composition in vivo | 伊万·加拉宁 | 2021-08-13 | — | — | CN | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101683341-A | Levobupivacaine and levisoprenaline contained frozen dry powder preparation for injection | STAR LAKE BIOSCIENCE CO INC ZH | 2010-03-31 | — | — | CN | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-3345919-B1 | BINDING DOMAINS DIRECTED AGAINST GPCR: G PROTEIN COMPLEXES AND USES DERIVED THEREOF | VIB VZW (BE) | 2026-04-01 | — | — | EP | disclosed |
| CN-120916785-A | Methods of treating corneal lesions | 林颂然 | 2025-11-07 | — | — | CN | disclosed |
| US-12459912-B2 | Advantageous benzothiophene compositions for mental disorders or enhancement | TACTOGEN INC (US) | 2025-11-04 | — | — | US | disclosed |
| EP-4635987-A2 | NOVEL ANTIGEN-BINDING CHIMERIC PROTEINS AND METHODS AND USES THEREOF | VIB VZW (BE) | 2025-10-22 | — | — | EP | disclosed |
| EP-3704160-B1 | NOVEL ANTIGEN-BINDING CHIMERIC PROTEINS AND METHODS AND USES THEREOF | VIB VZW (BE) | 2025-08-20 | — | — | EP | disclosed |
| WO-1981000849-A1 | NOVEL PROCESS AND INTERMEDIATES USEFUL IN THE PREPARATION OF SYMPATHOMIMETIC AMINES | INTERX RESEARCH CORP (US) | 1981-04-02 | — | — | WO | disclosed |
| US-4127675-A | BETA-RECEPTOR ANTAGONISTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1978-11-28 | — | — | US | disclosed |
| US-4116949-A | WATER-SOLUBLE, PHYSIOLOGICALLY ACTIVE, SYNTHETIC COPOLYPEPTIDES | THE REAGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1978-09-26 | — | — | US | disclosed |
| US-4045482-A | ADRENERGIC B-RECEPTOR BLOCKING AGENTS | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JA) | 1977-08-30 | — | — | US | disclosed |
| US-4004028-A | BRONCHODILATION | SMITHKLINE CORPORATION (US) | 1977-01-18 | — | — | US | disclosed |
| US-3961076-A | BRONCHODILATORS | SMITHKLINE CORPORATION (US) | 1976-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459912-B2 | Advantageous benzothiophene compositions for mental disorders or enhancement | SLC6A3, CREBBP, SLC1A2 | ADRB2 1106/4885ADRB1 1771/4885ADRB3 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.